ghk cu clinicaltrials gov GHK-Cu | Research Peptide Injectable GHK-Cu Peptide - COA
Description
Users frequently report improvements in joint flexibility and reductions in stiffness
The FDA has categorized it as a significant safety risk and has prohibited its use in compounding pharmacies, significantly restricting the channels through which it was previously being administered to patients in clinical settings
The incubates were then spun through Bio-Gel P6 spin columns (400 packed volume) for 1 min to separate free and bound 3 H-Hinge and the eluent was collected
No pain when injecting, but getting pain within the hour and lasting until the next day but lessening writhing 24 hours
